Exelixis Company Profile (NASDAQ:EXEL)

About Exelixis (NASDAQ:EXEL)

Exelixis logoExelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:EXEL
  • CUSIP: 30161Q10
  • Web: www.exelixis.com
Capitalization:
  • Market Cap: $7.82471 billion
  • Outstanding Shares: 292,512,000
Average Prices:
  • 50 Day Moving Avg: $23.04
  • 200 Day Moving Avg: $21.23
  • 52 Week Range: $8.47 - $27.63
P/E:
  • Trailing P/E Ratio: 1285.24
  • Foreward P/E Ratio: 49.07
  • P/E Growth: 3.17
Sales & Book Value:
  • Annual Revenue: $256.91 million
  • Price / Sales: 30.73
  • Book Value: $0.41 per share
  • Price / Book: 65.83
Profitability:
  • EBIDTA: $43.6 million
  • Net Margins: 1.37%
  • Return on Equity: 126.82%
  • Return on Assets: 3.15%
Debt:
  • Current Ratio: 2.31%
  • Quick Ratio: 2.30%
Misc:
  • Average Volume: 4.25 million shs.
  • Beta: 1.88
  • Short Ratio: 4.86
 

Frequently Asked Questions for Exelixis (NASDAQ:EXEL)

What is Exelixis' stock symbol?

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

How were Exelixis' earnings last quarter?

Exelixis, Inc. (NASDAQ:EXEL) released its earnings results on Monday, May, 1st. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.06. The business had revenue of $80.90 million for the quarter, compared to analyst estimates of $65.23 million. Exelixis had a return on equity of 126.82% and a net margin of 1.37%. Exelixis's revenue was up 425.3% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.27) earnings per share. View Exelixis' Earnings History.

When will Exelixis make its next earnings announcement?

Exelixis is scheduled to release their next quarterly earnings announcement on Tuesday, August, 1st 2017. View Earnings Estimates for Exelixis.

Where is Exelixis' stock going? Where will Exelixis' stock price be in 2017?

11 brokers have issued 1-year price targets for Exelixis' shares. Their predictions range from $8.00 to $33.00. On average, they anticipate Exelixis' stock price to reach $19.80 in the next twelve months. View Analyst Ratings for Exelixis.

What are analysts saying about Exelixis stock?

Here are some recent quotes from research analysts about Exelixis stock:

  • 1. Cann analysts commented, "Exelixis, Inc. announced today a settlement of the company’s dispute with Genentech, a member of the Roche Group, concerning the parties’ collaboration for the development and commercialization of Cotellic (cobimetinib). As part of the settlement, effective July 1, 2017, the companies have amended the existing Collaboration Agreement to revise the revenue and cost-sharing arrangements for the collaboration. The Amendment resolves the companies’ dispute pursuant to the arbitration demand filed on June 3, 2016." (7/20/2017)
  • 2. According to Zacks Investment Research, "Exelixis received a major boost with the FDA approval of Cabometyx tablets in Apr 2016. Initial uptake of the drug was encouraging and is expected to propel the top line in the forthcoming quarters in 2017. The sequential increase in Cabometyx sales is also a positive. Moreover, Cabometyx was also approved in the EU. Meanwhile, Exelixis is developing cabozantinib in a broad development program and plans to file a supplemental New Drug Application (sNDA) in the third quarter of 2017 for advanced RCC. A potential label expansion will further boost sales. Exelixis also has collaborations with Bristol-Myers and Roche on the development of cabozantinib in combination with immunotherapy agents. Exelixis’ share price outperformed the Zacks classified Biomedical and Genetics industry year to date. However, the company is heavily dependent on Cabometyx for growth now.  Operating expenses are also projected to increase." (7/11/2017)

Are investors shorting Exelixis?

Exelixis saw a decline in short interest in the month of June. As of June 30th, there was short interest totalling 15,465,148 shares, a decline of 12.5% from the June 15th total of 17,681,775 shares. Based on an average daily trading volume, of 7,594,749 shares, the short-interest ratio is presently 2.0 days. Currently, 5.5% of the company's shares are short sold.

Who are some of Exelixis' key competitors?

Who are Exelixis' key executives?

Exelixis' management team includes the folowing people:

  • Stelios B. Papadopoulos Ph.D., Independent Chairman of the Board, Co-Founder
  • Michael M. Morrissey Ph.D., President, Chief Executive Officer, Director
  • Christopher J. Senner, Chief Financial Officer, Executive Vice President
  • Gisela M. Schwab M.D., President - Product Development and Medical Affairs, Chief Medical Officer
  • Peter Lamb Ph.D., Executive Vice President - Scientific Strategy, Chief Scientific Officer
  • Jeffrey J. Hessekiel J.D., Executive Vice President, General Counsel, Secretary
  • Patrick Haley, Senior Vice President - Commercial
  • Charles M. Cohen Ph.D., Independent Director
  • Carl B. Feldbaum Esq., Independent Director
  • Alan M. Garber M.D. Ph.D., Independent Director

Who owns Exelixis stock?

Exelixis' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Handelsbanken Fonder AB (0.12%), Bank of Montreal Can (0.04%), Handelsinvest Investeringsforvaltning (0.03%), Creative Planning (0.03%), Aperio Group LLC (0.02%) and Meeder Asset Management Inc. (0.00%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Institutional Ownership Trends for Exelixis.

Who sold Exelixis stock? Who is selling Exelixis stock?

Exelixis' stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can. Company insiders that have sold Exelixis stock in the last year include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Insider Buying and Selling for Exelixis.

Who bought Exelixis stock? Who is buying Exelixis stock?

Exelixis' stock was bought by a variety of institutional investors in the last quarter, including Creative Planning, Handelsinvest Investeringsforvaltning, Capstone Asset Management Co., First Quadrant L P CA, Meeder Asset Management Inc. and Aperio Group LLC. View Insider Buying and Selling for Exelixis.

How do I buy Exelixis stock?

Shares of Exelixis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Exelixis' stock price today?

One share of Exelixis stock can currently be purchased for approximately $26.99.


MarketBeat Community Rating for Exelixis (NASDAQ EXEL)
Community Ranking:  2.8 out of 5 ( )
Outperform Votes:  183 (Vote Outperform)
Underperform Votes:  149 (Vote Underperform)
Total Votes:  332
MarketBeat's community ratings are surveys of what our community members think about Exelixis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Exelixis (NASDAQ:EXEL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Hold Ratings, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.64)
Consensus Price Target: $19.80 (26.66% downside)

Analysts' Ratings History for Exelixis (NASDAQ:EXEL)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/20/2017CannReiterated RatingHoldLowView Rating Details
7/13/2017SunTrust Banks, Inc.Initiated CoverageBuy -> Buy$33.00MediumView Rating Details
6/26/2017William BlairReiterated RatingOutperformMediumView Rating Details
6/12/2017Oppenheimer Holdings, Inc.Initiated CoverageHoldLowView Rating Details
3/31/2017Needham & Company LLCInitiated CoverageBuy -> Buy$28.00MediumView Rating Details
3/16/2017CIBCInitiated CoverageMarket Perform -> Market PerformHighView Rating Details
2/28/2017Stifel NicolausDowngradeBuy -> Hold$22.00N/AView Rating Details
1/24/2017Cowen and CompanyReiterated RatingOutperformN/AView Rating Details
11/3/2016Deutsche Bank AGInitiated CoverageBuy$17.00N/AView Rating Details
10/10/2016Piper Jaffray CompaniesUpgradeNeutral -> OverweightN/AView Rating Details
10/7/2016Leerink SwannReiterated RatingPositive$15.00N/AView Rating Details
9/28/2016S&P Equity ResearchBoost Price Target$13.41 -> $15.57N/AView Rating Details
(Data available from 7/21/2015 forward)

Earnings

Earnings History for Exelixis (NASDAQ:EXEL)
Earnings by Quarter for Exelixis (NASDAQ:EXEL)
Earnings History by Quarter for Exelixis (NASDAQ EXEL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2017        
5/1/2017Q1 2017($0.01)$0.05$65.23 million$80.90 millionViewListenView Earnings Details
2/27/2017Q416($0.01)$0.12$64.88 million$77.58 millionViewListenView Earnings Details
11/3/2016Q316($0.13)($0.04)$43.15 million$62.19 millionViewN/AView Earnings Details
8/3/2016Q216($0.27)($0.16)$16.76 million$36.25 millionViewListenView Earnings Details
5/4/2016Q116($0.25)($0.27)$9.11 million$15.40 millionViewListenView Earnings Details
2/29/2016Q415($0.22)($0.19)$8.16 million$9.94 millionViewListenView Earnings Details
11/10/2015Q315($0.20)($0.22)$9.08 million$9.85 millionViewListenView Earnings Details
8/11/2015Q215($0.21)($0.22)$8.69 million$8.00 millionViewListenView Earnings Details
4/30/2015Q115($0.24)($0.18)$8.08 million$9.40 millionViewListenView Earnings Details
2/24/2015Q414($0.31)($0.30)$7.50 million$7.35 millionViewListenView Earnings Details
11/4/2014Q314($0.37)($0.32)$6.77 million$6.30 millionViewListenView Earnings Details
7/31/2014Q214($0.39)($0.38)$5.66 million$6.56 millionViewListenView Earnings Details
5/1/2014Q114($0.37)($0.39)$6.11 million$4.90 millionViewListenView Earnings Details
2/20/2014Q413($0.38)($0.38)$5.71 million$4.34 millionViewListenView Earnings Details
10/30/2013Q313($0.37)($0.36)$5.55 million$5.50 millionViewListenView Earnings Details
8/6/2013Q2 2013($0.30)($0.34)$6.55 million$11.90 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.29)($0.24)$5.33 million$9.70 millionViewListenView Earnings Details
2/21/2013Q4 2012($0.24)($0.28)$9.46 million$7.80 millionViewListenView Earnings Details
11/7/2012Q312($0.30)($0.20)$9.22 million$13.30 millionViewN/AView Earnings Details
8/2/2012($0.27)($0.25)ViewN/AView Earnings Details
5/3/2012($0.19)($0.18)ViewN/AView Earnings Details
10/27/2011$0.57$0.60ViewN/AView Earnings Details
8/4/2011($0.17)($0.16)ViewN/AView Earnings Details
5/3/2011($0.19)($0.24)ViewN/AView Earnings Details
2/22/2011($0.21)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Exelixis (NASDAQ:EXEL)
2017 EPS Consensus Estimate: $0.06
2018 EPS Consensus Estimate: $0.32
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.03)$0.01($0.01)
Q2 20174$0.01$0.03$0.02
Q3 20174$0.00$0.03$0.02
Q4 20174$0.00$0.04$0.03
Q1 20181$0.06$0.06$0.06
Q2 20181$0.07$0.07$0.07
Q3 20181$0.09$0.09$0.09
Q4 20181$0.10$0.10$0.10
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Exelixis (NASDAQ:EXEL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Exelixis (NASDAQ:EXEL)
Insider Ownership Percentage: 5.10%
Institutional Ownership Percentage: 80.82%
Insider Trades by Quarter for Exelixis (NASDAQ:EXEL)
Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)
Insider Trades by Quarter for Exelixis (NASDAQ:EXEL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/30/2017Patrick J. HaleyInsiderSell5,000$18.46$92,300.00View SEC Filing  
5/15/2017Carl B FeldbaumDirectorSell32,988$21.58$711,881.04View SEC Filing  
5/10/2017Michael MorrisseyInsiderSell211,300$21.87$4,621,131.00View SEC Filing  
5/9/2017Michael MorrisseyCEOSell100,000$21.69$2,169,000.00View SEC Filing  
5/8/2017Michael MorrisseyCEOSell11,300$21.81$246,453.00View SEC Filing  
5/5/2017Michael MorrisseyInsiderSell259,149$22.24$5,763,473.76View SEC Filing  
5/1/2017Gisela SchwabCMOSell89,910$23.01$2,068,829.10View SEC Filing  
4/3/2017Vincent T MarchesiDirectorSell10,000$21.30$213,000.00View SEC Filing  
3/31/2017Jack L WyszomierskiDirectorSell5,150$21.57$111,085.50View SEC Filing  
3/27/2017Jeffrey HessekielEVPSell6,884$21.02$144,701.68View SEC Filing  
3/22/2017Jeffrey HessekielEVPSell23,787$20.54$488,584.98View SEC Filing  
3/20/2017Stelios PapadopoulosDirectorSell10,000$21.66$216,600.00View SEC Filing  
3/13/2017Charles CohenDirectorSell10,000$21.82$218,200.00View SEC Filing  
3/10/2017Vincent T MarchesiDirectorSell40,000$21.98$879,200.00View SEC Filing  
3/6/2017Michael MorrisseyInsiderSell200,000$22.72$4,544,000.00View SEC Filing  
3/3/2017Christopher J. SennerCFOSell11,000$22.80$250,800.00View SEC Filing  
3/2/2017George PosteDirectorSell76,250$22.53$1,717,912.50View SEC Filing  
1/3/2017Peter LambEVPSell70,000$14.65$1,025,500.00View SEC Filing  
12/16/2016Carl B. FeldbaumDirectorSell25,000$17.03$425,750.00View SEC Filing  
12/9/2016Alan M. GarberDirectorSell7,832$16.90$132,360.80View SEC Filing  
12/7/2016George A. ScangosDirectorSell204,894$17.81$3,649,162.14View SEC Filing  
12/5/2016George A. ScangosDirectorSell204,718$17.81$3,646,027.58View SEC Filing  
12/1/2016Gisela SchwabInsiderSell22,000$16.73$368,060.00View SEC Filing  
12/1/2016Peter LambEVPSell70,000$16.66$1,166,200.00View SEC Filing  
8/4/2016Gisela SchwabInsiderSell42,338$11.00$465,718.00View SEC Filing  
5/11/2016Lance WillseyDirectorBuy60,000$4.97$298,200.00View SEC Filing  
5/9/2016Lance WillseyDirectorBuy40,000$4.97$198,800.00View SEC Filing  
12/11/2015Lance WillseyDirectorBuy100,000$4.89$489,000.00View SEC Filing  
10/16/2015Peter LambEVPSell51,549$5.80$298,984.20View SEC Filing  
10/13/2015Peter LambEVPSell600$5.80$3,480.00View SEC Filing  
10/12/2015Peter LambEVPSell300,276$5.84$1,753,611.84View SEC Filing  
9/17/2014Vincent T MarchesiDirectorBuy20,000$1.71$34,200.00View SEC Filing  
8/29/2013Lance WillseyDirectorBuy10,000$5.15$51,500.00View SEC Filing  
12/20/2012Vincent T MarchesiDirectorBuy4,000$4.68$18,720.00View SEC Filing  
12/19/2012Vincent T MarchesiDirectorBuy6,000$4.72$28,320.00View SEC Filing  
12/10/2012Gisela SchwabEVPBuy25,000$4.39$109,750.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Exelixis (NASDAQ:EXEL)
Latest Headlines for Exelixis (NASDAQ:EXEL)
Source:
DateHeadline
streetinsider.com logoExelixis (EXEL), Genentech Reach Settlement in Dispute Regarding Companies' Collaboration Agreement for Cobimetinib
www.streetinsider.com - July 20 at 9:10 PM
reuters.com logoBRIEF-Exelixis announces settlement of dispute with Genentech
www.reuters.com - July 20 at 9:10 PM
businesswire.com logoExelixis Announces Settlement of Dispute with Genentech ... - Business Wire (press release)
www.businesswire.com - July 20 at 4:06 PM
finance.yahoo.com logoExelixis Announces Settlement of Dispute with Genentech Regarding Companies’ Collaboration Agreement for Cobimetinib
finance.yahoo.com - July 20 at 4:06 PM
americanbankingnews.com logoExelixis, Inc. (EXEL) Stock Rating Reaffirmed by Cann
www.americanbankingnews.com - July 20 at 11:36 AM
seekingalpha.com logoExelixis up 2% on settlement of cobimetinib collaboration spat with Genentech
seekingalpha.com - July 20 at 11:13 AM
seekingalpha.com logoUpdates To Exelixis Thesis: Management Continues To Execute - Seeking Alpha
seekingalpha.com - July 17 at 7:26 PM
finance.yahoo.com logoExelixis to Release Second Quarter 2017 Financial Results on Wednesday, August 2, 2017
finance.yahoo.com - July 17 at 7:26 PM
finance.yahoo.com logoCramer's lightning round: This business is better than people think
finance.yahoo.com - July 17 at 7:26 PM
americanbankingnews.com logoExelixis, Inc. (EXEL) Forecasted to Earn Q2 2017 Earnings of $0.01 Per Share
www.americanbankingnews.com - July 17 at 7:46 AM
americanbankingnews.com logoExelixis, Inc. (EXEL) Now Covered by Analysts at SunTrust Banks, Inc.
www.americanbankingnews.com - July 16 at 5:14 PM
rttnews.com logoCompany Spotlight: Exelixis
www.rttnews.com - July 16 at 10:25 AM
americanbankingnews.com logoShort Interest in Exelixis, Inc. (NASDAQ:EXEL) Declines By 12.5%
www.americanbankingnews.com - July 16 at 7:06 AM
nasdaq.com logoCompany Spotlight: Exelixis - Nasdaq
www.nasdaq.com - July 14 at 5:04 PM
nasdaq.com logoWhy Are Shares of Exelixis (EXEL) Up 77% So Far in 2017? - Nasdaq
www.nasdaq.com - July 14 at 12:51 AM
finance.yahoo.com logoWhy Exelixis (EXEL) Could Be an Impressive Growth Stock - Yahoo Finance
finance.yahoo.com - July 13 at 7:48 PM
finance.yahoo.com logoWhy Are Shares of Exelixis (EXEL) Up 77% So Far in 2017?
finance.yahoo.com - July 13 at 7:48 PM
americanbankingnews.com logoQ2 2017 Earnings Forecast for Exelixis, Inc. Issued By William Blair (EXEL)
www.americanbankingnews.com - July 12 at 7:46 AM
nasdaq.com logoExelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx - Nasdaq
www.nasdaq.com - July 11 at 7:39 PM
americanbankingnews.com logoExelixis, Inc. (EXEL) Forecasted to Post FY2017 Earnings of $0.17 Per Share
www.americanbankingnews.com - July 11 at 10:06 AM
americanbankingnews.com logoExelixis, Inc. (EXEL) Rating Increased to Strong-Buy at Zacks Investment Research
www.americanbankingnews.com - July 11 at 10:04 AM
thestreet.com logoBiotech Movers: Exelixis, Omeros, Inovio - TheStreet.com
www.thestreet.com - July 10 at 6:26 PM
finance.yahoo.com logoExelixis and Bristol-Myers Squibb Initiate Phase 3 Trial of Opdivo® in Combination with CABOMETYX™ or Opdivo and Yervoy® in Combination with CABOMETYX, Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
finance.yahoo.com - July 10 at 6:26 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: RXi Pharmaceuticals Corporation and Exelixis Inc.
finance.yahoo.com - July 10 at 6:26 PM
seekingalpha.com logoUK's advisor to NHS backs inclusion of Exelixis' Cabometyx for patients with advanced kidney cancer; shares up 1%
seekingalpha.com - July 10 at 1:27 PM
seekingalpha.com logoBristol Myers launches late-stage study assessing combination of Opdivo or Opdivo/Yervoy with Exelixis' Cabometyx in kidney cancer
seekingalpha.com - July 10 at 10:50 AM
seekingalpha.com logoExelixis: Great Stock, What's Next? - Seeking Alpha
seekingalpha.com - July 8 at 6:00 PM
fool.com logoThe Cabosun Shone on Exelixis in June, Sending Its Shares Up 32% - Motley Fool
www.fool.com - July 8 at 6:00 PM
finance.yahoo.com logoThis Biotech Finds Its Stride With Kidney Cancer Treatment
finance.yahoo.com - July 8 at 10:41 AM
americanbankingnews.com logo$85.12 Million in Sales Expected for Exelixis, Inc. (EXEL) This Quarter
www.americanbankingnews.com - July 8 at 9:38 AM
americanbankingnews.com logoExelixis, Inc. (EXEL) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 7 at 10:52 AM
fool.com logoThe Cabosun Shone on Exelixis in June, Sending Its Shares Up 32%
www.fool.com - July 7 at 8:34 AM
americanbankingnews.com logo Analysts Expect Exelixis, Inc. (EXEL) Will Post Earnings of $0.03 Per Share
www.americanbankingnews.com - July 6 at 2:36 PM
americanbankingnews.com logoExelixis, Inc. (NASDAQ:EXEL) Upgraded to Strong-Buy at Zacks Investment Research
www.americanbankingnews.com - July 4 at 11:04 AM
americanbankingnews.com logoExelixis, Inc. (EXEL) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - July 2 at 4:58 PM
seekingalpha.com logoAcadia Pharmaceuticals: Biotech Stocks In Renewed Price Interest
seekingalpha.com - June 29 at 7:58 PM
finance.yahoo.com logoExelixis Repays Deerfield Notes One Year Ahead of Maturity Date, Addressing Last Major Source of Indebtedness
finance.yahoo.com - June 29 at 7:58 PM
americanbankingnews.com logoShort Interest in Exelixis, Inc. (EXEL) Drops By 8.1%
www.americanbankingnews.com - June 29 at 7:18 AM
americanbankingnews.com logoExelixis, Inc. Expected to Post Q2 2017 Earnings of $0.01 Per Share (EXEL)
www.americanbankingnews.com - June 28 at 7:32 AM
finance.yahoo.com logoThis Drugmaker Flirts With Breakout As Some Biotechs Rally
finance.yahoo.com - June 26 at 11:12 PM
finance.yahoo.com logoThe Reason for the Big Rise in Biotech Stocks
finance.yahoo.com - June 26 at 6:11 PM
finance.yahoo.com logoBiotech Rally Gets Second Wind As This Small Cap Nears Breaks Out
finance.yahoo.com - June 26 at 6:11 PM
americanbankingnews.com logoExelixis, Inc. (EXEL) Receives "Outperform" Rating from William Blair
www.americanbankingnews.com - June 26 at 8:16 AM
fool.com logoBetter Buy: Exelixis, Inc. vs. Novartis AG - Motley Fool
www.fool.com - June 25 at 10:49 PM
finance.yahoo.com logoBetter Buy: Exelixis, Inc. vs. Novartis AG
finance.yahoo.com - June 24 at 5:28 PM
americanbankingnews.com logoBidaskClub Upgrades Exelixis, Inc. (EXEL) to Buy
www.americanbankingnews.com - June 23 at 9:32 PM
finance.yahoo.com logoBiotech Exelixis May Break Out On Cancer Drug Trial Results
finance.yahoo.com - June 22 at 5:43 PM
finance.yahoo.com logoExelixis, Inc. – Value Analysis (NASDAQ:EXEL) : June 22, 2017
finance.yahoo.com - June 22 at 5:43 PM
finance.yahoo.com logoAfter Celgene, Regeneron Breakouts, This Biotech Stock May Be Next
finance.yahoo.com - June 22 at 9:53 AM
finance.yahoo.com logoExelixis's Cabometyx Positive for First-Line Kidney Cancer
finance.yahoo.com - June 20 at 10:50 PM

Social

Chart

Exelixis (EXEL) Chart for Friday, July, 21, 2017

This page was last updated on 7/21/2017 by MarketBeat.com Staff